Michelle Gilson - 03 Aug 2026 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Reporting relationship: Director
Issuer ticker: RANI
Reported as of: 03 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2026, 20:51:54 UTC
Prior SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Carlos Perez, Attorney-in-Fact

Key filing fact

Michelle Gilson filed Form 4 for Rani Therapeutics Holdings, Inc. (RANI) on 04 Aug 2026.

Key facts

This page summarizes Michelle Gilson's Form 4 filing for Rani Therapeutics Holdings, Inc. (RANI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2026, 20:51.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001930862 Primary reporting owner

Gilson Michelle

Relationship: Director
Address: C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE
Signature: /s/ Carlos Perez, Attorney-in-Fact
Signature date: 04 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RANI transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value
Shares: +247,200
Change %
Price: $0.000000^*
Shares after: 247,200
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 247,200
Exercise price: $0.8013
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest and become exercisable over a three-year period, with 1/3rd of shares vesting on the first anniversary of the grant date and 1/36th of the shares vesting in equal monthly installments thereafter, such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date, and will vest in full upon a Change in Control (as defined in the 2021 Plan), subject to the Reporting Person's Continuous Service through such date.